Back to all papers

Dual deep learning approach for non-invasive renal tumour subtyping with VERDICT-MRI.

January 6, 2026pubmed logopapers

Authors

Sen S,Smith L,Caselton L,Clemente J,Tran M,Punwani S,Atkinson D,Hesketh RL,Panagiotaki E

Affiliations (6)

  • UCL Hawkes Institute, 90 High Holborn, London, UK. [email protected].
  • UCL Centre for Medical Imaging, Charles Bell House, London, UK.
  • UCL Advanced Research Computing Centre, 90 High Holborn, London, UK.
  • UCL Division of Surgery and Interventional Science, London, UK.
  • UCL Department of Imaging, Charles Bell House, London, UK.
  • UCL Hawkes Institute, 90 High Holborn, London, UK.

Abstract

Renal cell carcinomas (RCCs) have multiple subtypes that are difficult to distinguish using imaging alone. This study characterises renal tumour microstructure using diffusion MRI (dMRI) and the Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumours (VERDICT)-MRI framework. Patients were prospectively recruited from the RIM trial (ClinicalTrials.gov: NCT07173140, 20/11/2024). Fourteen patients with 17 renal tumours (including benign and various RCC subtypes) underwent dMRI using nine b-values (0-2500 s/mm²). A three-compartment VERDICT model was fitted with a self-supervised neural network. Compared to simpler dMRI models, VERDICT more accurately captured the diffusion data in tumour and healthy tissue. VERDICT revealed significant differences in intracellular volume fraction between cancerous and normal tissue, and in vascular volume fraction between vascular and non-vascular regions. A feature selection method identified a reduced 4 b-value protocol (b = [70, 150, 1000, 2000]), cutting scan time by over 30 min, enabling more efficient imaging in larger cohorts.

Topics

Journal Article

Ready to Sharpen Your Edge?

Subscribe to join 8,000+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.